Sun X, Lee J, Navas T, Baldwin D T, Stewart T A, Dixit V M
Departments of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080, USA.
J Biol Chem. 1999 Jun 11;274(24):16871-5. doi: 10.1074/jbc.274.24.16871.
RIP3 is a novel gene product containing a N-terminal kinase domain that shares extensive homology with the corresponding domain in RIP (receptor-interacting protein) and RIP2. Unlike RIP, which has a C-terminal death domain, and RIP2, which has a C-terminal caspase activation and recruitment domain, RIP3 has a unique C terminus. RIP3 binds RIP through its unique C-terminal segment and by virtue of this interaction is recruited to the tumor necrosis factor (TNF) receptor-1 signaling complex. Previous studies have shown that RIP mediates TNF-induced activation of the anti-apoptotic NF-kappaB pathway. RIP3, however, attenuates both RIP and TNF receptor-1-induced NF-kappaB activation. Overexpression studies revealed RIP3 to be a potent inducer of apoptosis, capable of selectively binding to large prodomain initiator caspases.
RIP3是一种新型基因产物,含有一个N端激酶结构域,该结构域与RIP(受体相互作用蛋白)和RIP2中的相应结构域具有广泛的同源性。与具有C端死亡结构域的RIP以及具有C端半胱天冬酶激活和募集结构域的RIP2不同,RIP3具有独特的C末端。RIP3通过其独特的C端片段与RIP结合,并凭借这种相互作用被募集到肿瘤坏死因子(TNF)受体-1信号复合物中。先前的研究表明,RIP介导TNF诱导的抗凋亡NF-κB途径的激活。然而,RIP3会减弱RIP和TNF受体-1诱导的NF-κB激活。过表达研究表明,RIP3是一种有效的凋亡诱导剂,能够选择性地与大型前结构域起始半胱天冬酶结合。